![](https://www.lachmanconsultants.com/wp-content/themes/lac/wp-content/uploads/2023/02/missing-thumbnail.jpg)
What’s in a Name? GPhA Says, Everything-for Biosimilars!
GPhA filed a Citizens Petition on September 19, asking FDA to implement its INN naming policy equally to all biologics, and, in the Petition, articulated all the arguments as to why this is a necessity for future biosimilars being approved by FDA.